Treatment effect of aspirin for primary prevention does not differ according to baseline ASCVD risk

Ann Intern Med. 2020 Oct 20;173(8):JC39. doi: 10.7326/ACPJ202010200-039.

Authors

Sean P Haley¹, Alexander Chessman¹

Affiliation

¹ Medical University of South Carolina, Charleston, South Carolina, USA (S.P.H., A.C.).

PMID: 33075272
DOI: 10.7326/ACPJ202010200-039

Abstract

Nudy M, Cooper J, Ghahramani M, et al. Aspirin for primary atherosclerotic cardiovascular disease prevention as baseline risk increases: a meta-regression analysis. Am J Med. 2020;133:1056-64. 32445718.

Publication types

Comment

MeSH terms

Aspirin / therapeutic use
Atherosclerosis* / prevention & control
Cardiovascular Diseases* / prevention & control
Humans
Primary Prevention
Regression Analysis

Substances

Aspirin